616 related articles for article (PubMed ID: 25477334)
1. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
2. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
3. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
4. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
6. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
7. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma.
Qiu SJ; Ye SL; Wu ZQ; Tang ZY; Liu YK
J Cancer Res Clin Oncol; 1998; 124(5):253-8. PubMed ID: 9645455
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
9. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Zhang X; Zhang Z; Cheng J; Li M; Wang W; Xu W; Wang H; Zhang R
J Biol Chem; 2012 Aug; 287(36):30468-76. PubMed ID: 22787160
[TBL] [Abstract][Full Text] [Related]
11. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
[TBL] [Abstract][Full Text] [Related]
12. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
13. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
14. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.
Li Q; Liu X; Jin K; Lu M; Zhang C; Du X; Xing B
BMC Cancer; 2017 Aug; 17(1):605. PubMed ID: 28859621
[TBL] [Abstract][Full Text] [Related]
15. [ShRNA-mediated silencing of MDM2 inhibits growth of HepG2 hepatocellular carcinoma cells xenografted in nude mice].
Zhao YY; Li YG; Sun YJ; Liu HP; Yang ZC; Zhang DD; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):213-7. PubMed ID: 23967744
[TBL] [Abstract][Full Text] [Related]
16. Genomic gain of
Cao P; Yang A; Li P; Xia X; Han Y; Zhou G; Wang R; Yang F; Li Y; Zhang Y; Cui Y; Ji H; Lu L; He F; Zhou G
Sci Adv; 2021 Aug; 7(35):. PubMed ID: 34433556
[TBL] [Abstract][Full Text] [Related]
17. [Role of functional inactivation of p53 from MDM2 overexpression in hepatocarcinogenesis].
Luo YL; Cheng RX; Feng DY
Hunan Yi Ke Da Xue Xue Bao; 2001 Feb; 26(1):13-6. PubMed ID: 12536604
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
[TBL] [Abstract][Full Text] [Related]
19. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
[TBL] [Abstract][Full Text] [Related]
20. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]